UK is losing market share in pharmaceutical researchBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7268.1041/b (Published 28 October 2000) Cite this as: BMJ 2000;321:1041
- Richard Smith
The NHS is becoming a steadily less attractive place for pharmaceutical companies to conduct clinical trials. That was the message delivered last week by Tadataka Yamada, chairman of research and development for SmithKline Beecham, at a meeting on how to make research and development in London more attractive to funders.
Pharmaceutical clinical research has increased worldwide in the past decade, but Britain's market share has fallen, even though the absolute quantity has remained about the same. The industry spends …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial